US Patent Issued to Enliven on Sept. 15 for "Fused tetracyclic quinazoline derivatives as inhibitors of ERBB2" (American, Chinese Inventors)

ALEXANDRIA, Va., Sept. 15 -- United States Patent no. 12,735,434, issued on Sept. 15, was assigned to Enliven Inc. (Burlingame, Calif.).

"Fused tetracyclic quinazoline derivatives as inhibitors of ERBB2" was invented by Joseph P. Lyssikatos (Boulder, Colo.), Samuel Kintz (Boulder, Colo.), Li Ren (Superior, Colo.) and Qiang Su (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin...